For patients with pathogenic variants of the genes BRCA1/BRCA2, the OlympiA trial achieved positive results in a high-risk population of hormone receptor-positive, HER2-negative breast cancers and variants of the genes BRCA1/BRCA2 [58]. Here, NR4A1 is linked to breast carcinoma.